Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CNTX 
Context Therapeutics Inc (CNTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CNTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.2
1 Year Target Price $5.2
| 2 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -27.98% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 77.15M USD | Price to earnings Ratio - | 1Y Target Price 5.2 |
Price to earnings Ratio - | 1Y Target Price 5.2 | ||
Volume (30-day avg) 5 | Beta 1.89 | 52 Weeks Range 0.49 - 2.59 | Updated Date 08/28/2025 |
52 Weeks Range 0.49 - 2.59 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.43 |
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.0592 | Actual -0.09 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.22% | Return on Equity (TTM) -37.25% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -6204122 | Price to Sales(TTM) - |
Enterprise Value -6204122 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.6 | Shares Outstanding 89704200 | Shares Floating 37696393 |
Shares Outstanding 89704200 | Shares Floating 37696393 | ||
Percent Insiders 2.33 | Percent Institutions 76.79 |
Upturn AI SWOT
Context Therapeutics Inc
Company Overview
History and Background
Context Therapeutics Inc. (formerly Integral Molecular) was founded in 2006. It is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for hormone-driven cancers. The company is headquartered in Philadelphia, Pennsylvania.
Core Business Areas
- Apremilast: Development of onapristone extended release (ONA-XR), an investigational Phase 3 drug for hormone-driven cancers.
Leadership and Structure
Martin Lehr (CEO), James Vena (CFO), Dr. Jennifer Wheler (Chief Medical Officer). The company has a board of directors with members from various venture capital and pharmaceutical backgrounds.
Top Products and Market Share
Key Offerings
- Onapristone Extended Release (ONA-XR): ONA-XR is an investigational, proprietary Phase 3 product candidate for the treatment of hormone-driven cancers, initially focusing on progesterone receptor positive (PR+) breast cancer. As it is still in clinical trials, it has no current market share or revenue. Competitors in the breast cancer space include companies developing endocrine therapies, CDK4/6 inhibitors, and targeted therapies. Some competitors are Novartis (Kisqali), Pfizer (Ibrance), and AstraZeneca (Faslodex).
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically in oncology, is highly competitive and rapidly evolving with continuous advancements in treatment options. The market is driven by an increasing incidence of cancer, aging populations, and technological advancements in drug development.
Positioning
Context Therapeutics is a clinical-stage company attempting to establish itself in the market for hormone-driven cancers. Their competitive advantage, if any, would rely on the success of ONA-XR's clinical trials and subsequent FDA approval and commercialization.
Total Addressable Market (TAM)
The global breast cancer therapeutics market is estimated to be worth billions of dollars. Context Therapeutics' positioning relative to the TAM depends on successful commercialization of ONA-XR, specifically targeting PR+ breast cancer. Exact share of TAM is dependent on adoption post-approval.
Upturn SWOT Analysis
Strengths
- Proprietary drug candidate (ONA-XR)
- Focus on a specific subtype of breast cancer (PR+)
- Experienced management team
- Phase 3 clinical trial progress
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on a single lead product candidate
- Clinical trial risks and regulatory hurdles
- Lack of commercialization infrastructure
Opportunities
- Positive clinical trial results for ONA-XR
- FDA approval and market launch of ONA-XR
- Partnerships with larger pharmaceutical companies
- Expansion to other hormone-driven cancers
Threats
- Failure of ONA-XR in clinical trials
- Regulatory setbacks
- Competition from existing and emerging therapies
- Patent challenges
- Inability to secure adequate funding
Competitors and Market Share
Key Competitors
- NVS
- PFE
- AZN
Competitive Landscape
Context Therapeutics faces significant competition from established pharmaceutical companies. Its advantages would stem from a unique mechanism of action and/or superior efficacy and safety of ONA-XR, if proven in clinical trials. It lacks the resources and established market presence of its larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical and clinical development of ONA-XR.
Future Projections: Future growth is dependent on the successful completion of Phase 3 trials, FDA approval, and commercialization of ONA-XR. Analyst projections would be needed for specific growth rates.
Recent Initiatives: Recent initiatives include advancing the Phase 3 trial for ONA-XR in PR+ breast cancer.
Summary
Context Therapeutics is a high-risk, high-reward clinical-stage company focusing on hormone-driven cancers. Its success hinges on the outcome of ONA-XR's Phase 3 trial and subsequent regulatory approval. While it has a focused approach and experienced management, it faces strong competition and financial constraints. The company needs to demonstrate significant clinical efficacy to differentiate itself and attract partnerships or investment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. The information provided is for informational purposes only and may not be entirely accurate or complete. Investments in pharmaceutical companies are speculative and involve substantial risk of loss.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Context Therapeutics Inc
Exchange NASDAQ | Headquaters Philadelphia, PA, United States | ||
IPO Launch date 2021-10-20 | Co-Founder, President, CEO & Director Mr. Martin A. Lehr | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | |
Full time employees 12 | |||
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.